British journal of clinical pharmacology
-
Br J Clin Pharmacol · Oct 2017
Randomized Controlled Trial Multicenter StudyTreatment of spontaneous preterm labour with retosiban: a phase II pilot dose-ranging study.
The aims of the present study were to investigate the maternal, fetal and neonatal safety and tolerability, pharmacodynamics and pharmacokinetics of intravenous (IV) retosiban in pregnant women with spontaneous preterm labour (PTL) between 340/7 and 356/7 weeks' gestation. ⋯ Intravenous retosiban has a favourable safety and tolerability profile and might prolong pregnancies in women with PTL. The study provides the rationale and dosing strategy for further evaluation of the efficacy of retosiban in the treatment of PTL.